| DB ID | MyCo_2488 |
| Title | Relationship between anti-fungal effects and lung exposure of PC945, a novel inhaled antifungal agent, in Aspergillus fumigatus infected mice: Pulmonary PK-PD analysis of anti-fungal PC945 |
| Year | 2021 |
| PMID | 34015430 |
| Fungal Diseases involved | Aspergillus fumigatus infection |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | All animal studies and class II pathogen use were approved by the Ethics Review Committee for Animal Experimentation of Nihon University and the Microbial safet Management Committee of Nihon University School of Pharmacy (E-H25-001). |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Animal |
| Host Common name | Mice |
| Host Scientific name | Mus musculus |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | UK |
| Cohort | Intact non-infected A/J mice (males, 25-30g, Envigo Ltd., UK) were also used for a pharmacokinetic study at Pneumolabs (UK) Ltd. [Phramidex] (Middlesex, UK). |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | ELISA Kit- Platelia Aspergillus (Platelia Aspergillus EIA; Bio-Rad Laboratories, Redmond, WA, USA) |
| Assay Data | None |
| Validation Techniques used | FDA Approved -Platelia Aspergillus ELISA |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
